Clinical Trial: Clinical Study of AFN50 Injection in the Autoimmune Diseases

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07408336) titled 'Clinical Study of AFN50 Injection in the Autoimmune Diseases' on Feb. 04.

Brief Summary: This is an investigator-initiated trial designed to evaluate the safety, tolerability and primary efficacy of AFN50 injection for the treatment of autoimmune diseases.

Study Start Date: Feb. 04

Study Type: INTERVENTIONAL

Condition: Autoimmune Diseases

Intervention: BIOLOGICAL: AFN50 injection

Intravenous infusion therapy. AFN50 was developed using novel T-cell-targeted lipid nanoparticles (T-LNP) encapsulating mRNA encoding Chimeric Antigen Receptor.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: AlphaNa Bioscience Company Limited

Pub...